SUMMARY
Enterovirus 71 (EV71) infection and its associated hand-foot-mouth disease is a significant public health problem. The purpose of this study is to
develop a novel vaccine to prevent EV71 infection. Bacillus subtilis spores were engineered to express VP1 protein of EV71 with CotB as carrier
protein. The recombination was tested in adult mice for the ability to induce immune responses. Mice were inoculated orally and intranasally
simultaneously with the spores. The vaccine’s efficacy on stimulating immune responses was evaluated by measuring the titer of anti-VP1 IgG and IgA
with enzyme-linked-immunosorbent serologic assay (ELISA), and the number of VP1-specific T cells by ELIS-POT. Serum titers of IgG (0.41±0.05 vs
0.20±0.07) and IgA (0.24±0.02 vs 0.11±0.01) in mice immunized with recombinant CotB-VP1 spores were higher than that of mice immunized with
nonrecombinant spores 1A771. Splenocytes from the group of mice receiving VP1 spores vaccination contained 1.69±0.52/104 VP1-specific T
cells, which was greater than the 0.06±0.06/104 cells from the group of mice receiving nonrecombinant spores vaccination. In conclusion,
Bacillus subtilis spores displaying VP1 of EV71 are effective in stimulating cellular immunity and humoral immunity in mice.
KEY WORDS
enterovirus 71; immunity; vaccine; Bacillus subtilis spores
REFERENCES
Barnes AG, Cerovic V, Hobson PS, Klavinskis LS. Bacillus subtilis spores: a novel microparticle adjuvant which can instruct a balanced Th1 and
Th2 immune response to specific antigen. Eur J Immunol. 37: 1538-1547, 2007.
[CrossRef]
[PubMed]
Berger J. The age of biomedicine: current trends in traditional subjects. J Appl Biomed. 9: 57-61, 2011.
[CrossRef]
[JAB]
Carrillo C, Wigdorovitz A, Oliveros JC, Zamorano PI, Sadir AM, Gómez N, Salinas J, Escribano JM, Borca MV. Protective Immune response to
foot-and-mouth disease virus with VP1 expressed in transgenic plants. J Virol. 72: 1688-1690, 1998.
[PubMed]
Caruso A, Flamminio G, Folghera S, Peroni L, Foresti I, Balsari A, Turano A. Expression of activation markers on peripheral-blood lymphocytes
following oral administration of Bacillus subtilis spores. Int J Immunopharmacol. 15: 87-92, 1993.
[CrossRef]
Ceragioli M, Cangiano G, Esin S, Ghelardi E, Ricca E, Senesi S. Phagocytosis, germination and killing of Bacillus subtilis spores presenting
heterologous antigens in human macrophages. Microbiology. 155: 338-346, 2009.
[CrossRef]
[PubMed]
Challacombe SJ. Salivary antibodies and systemic tolerance in mice after oral immunization with bacterial antigens. Ann N Y Acad Sci. 409: 177-193,
1983.
[CrossRef]
[PubMed]
Chan L, Parashar U, Lye M, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, Jegathesan M, Anderson LJ. Deaths of children
during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis.
31: 678-683, 2000.
[CrossRef]
[PubMed]
Chen HF, Chang MH, Chiang BL, Jeng ST. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine.
24: 2944-2951, 2006.
[CrossRef]
[PubMed]
Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF, Chen CM. Expression of VP1 protein in the milk of transgenic
mice: A potential oral vaccine protects against enterovirus 71 infection. Vaccine. 26: 2882-2889, 2008.
[CrossRef]
[PubMed]
Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT. An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg.
77: 188-191, 2007.
[PubMed]
Ciabattini A, Parigi R, Isticato R, Oggioni MR, Pozzi G. Oral priming of mice by recombinant spores of Bacillus subtilis. Vaccine. 22:
4139-4143, 2004.
[CrossRef]
[PubMed]
Cutting SM, Hong HA, Baccigalupi L, Ricca E. Oral vaccine delivery by recombinant spore probiotics. Int Rev Immunol. 28: 487-505, 2009.
[CrossRef]
[PubMed]
Duc le H, Hong HA, Cutting SM. Germination of the spore in the gastrointestinal tract provides a novel route for heterologous antigen delivery.
Vaccine. 21: 4215-4224, 2003.
[CrossRef]
Duc le H, Hong HA, Uyen NQ, Cutting SM. Intracellular fate and immunogenicity of B. subtilis spores. Vaccine. 22: 1873-1885, 2004.
[PubMed]
Duc le H, Hong HA, Atkins HS, Flick-Smith HC, Durrani Z, Rijpkema S, Titball RW, Cutting SM. Immunization against anthrax using Bacillus
subtilis spores expressing the anthrax protective antigen. Vaccine. 25: 346-355, 2007.
[PubMed]
Fais S, Pallone F, Nava C, Magnani M. Lymphocyte activation by B. subtilis spores. Boll Ist Sieroter Milan. 66: 391-394, 1987.
[PubMed]
Fakhry S, Sorrentini I, Ricca E, De Felice M, Baccigalupi L. Characterization of spore forming Bacilli isolated from the human gastrointestinal tract.
J Appl Microbiol. 105: 2178-2186, 2008.
[CrossRef]
[PubMed]
Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of
Enterovirus 71 using synthetic peptides. Virus Res. 125: 61-68, 2007.
[CrossRef]
[PubMed]
Hinc K, Isticato R, Dembek M, Karczewska J, Iwanicki A, Peszyńska-Sularz G, De Felice M, Obuchowski M, Ricca E. Expression and display of UreA of
Helicobacter acinonychis on the surface of Bacillus subtilis spores. Microb Cell Fact. 9: 2, 2010.
[CrossRef]
[PubMed]
Isticato R, Cangiano G, Tran HT, Ciabattini A, Medaglini D, Oggioni MR, De Felice M, Pozzi G, Ricca E. Surface Display of Recombinant Proteins on
Bacillus subtilis Spores. J Bacteriol. 183: 6294-6301, 2001.
[CrossRef]
[PubMed]
Kim JH, Roh C, Lee CW, Kyung D, Choi SK, Jung HC, Pan JG, Kim BG. Bacterial surface display of GFP(uv) on Bacillus subtilis spores. J Microbiol
Biotechnol. 17: 677-680, 2007.
[PubMed]
Knecht LD, Pasini P, Daunert S. Bacterial spores as platforms for bioanalytical and biomedical applications. Anal Bioanal Chem. 400: 977-989,
2011.
[CrossRef]
[PubMed]
Kosaka T, Maeda T, Nakada Y, Yukawa M, Tanaka S. Effect of Bacillus subtilis spore administration on activation of macrophages and natural
killer cells in mice. Vet Microbiol. 60: 215-225, 1998.
[CrossRef]
Lai EM, Phadke ND, Kachman MT, Giorno R, Vazquez S, Vazquez JA, Maddock JR, Driks A. Proteomic analysis of the spore coats of Bacillus subtilis
and Bacillus anthracis. J Bacteriol. 185: 1443-1454, 2003.
[CrossRef]
[PubMed]
Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines. 9: 149-156, 2010.
[CrossRef]
[PubMed]
Lee S, Belitsky BR, Brinker JP, Kerstein KO, Brown DW, Clements JD, Keusch GT, Tzipori S, Sonenshein AL, Herrmann JE. Development of a Bacillus
subtilis-Based Rotavirus Vaccine. Clin Vaccine Immunol. 17: 1647-1655, 2010.
[CrossRef]
[PubMed]
Li L, Hu X, Wu Z, Xiong S, Zhou Z, Wang X, Xu J, Lu F, Yu X. Immunogenicity of self-adjuvanticity oral vaccine candidate based on use of Bacillus
subtilis spore displaying Schistosoma japonicum 26 KDa GST protein. Parasitol Res. 105: 1643-1651, 2009.
[CrossRef]
[PubMed]
Luiz WB, Cavalcante RC, Paccez JD, Souza RD, Sbrogio-Almeida ME, Ferreira RC, Ferreira LC. Boosting systemic and secreted antibody responses in mice
orally immunized with recombinant Bacillus subtilis strains following parenteral priming with a DNA vaccine encoding the enterotoxigenic
Escherichia coli (ETEC) CFA/I fimbriae B subunit. Vaccine. 26: 3998-4005, 2008.
[CrossRef]
[PubMed]
Mauriello EM, Duc le H, Isticato R, Cangiano G, Hong HA, De Felice M, Ricca E, Cutting SM. Display of heterologous antigens on the Bacillus
subtilis spore coat using CotC as a fusion partner. Vaccine. 22: 1177-1187, 2004.
[CrossRef]
[PubMed]
Mauriello EM, Cangiano G, Maurano F, Saggese V, De Felice M, Rossi M, Ricca E. Germination-independent induction of cellular immune response by
Bacillus subtilis spores displaying the C fragment of the tetanus toxin. Vaccine. 25: 788-793, 2007.
[CrossRef]
[PubMed]
Oberste M S, Nix W A, Maher K, Pallansch M A. Improved molecular identification of enteroviruses by RT-PCR and amplicon sequencing. J Clin Virol. 26:
375-377, 2003.
[CrossRef]
Ogra PL, Fishaut M, Gallagher MR. Viral vaccination via the mucosal routes. Rev Infect Dis. 2: 352-369, 1980.
[CrossRef]
[PubMed]
Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 9: 1097-1105,
2010.
[CrossRef]
Potot S, Serra CR, Henriques AO, Schyns G. Display of Recombinant Proteins on Bacillus subtilis Spores, Using a Coat-Associated Enzyme as the
Carrier. Appl Environ Microb. 76: 5926-5933, 2010.
[CrossRef]
[PubMed]
Robinson K, Chamberlain LM, Schofield KM, Wells JM, Le Page RW. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis.
Nat Biotechnol. 15: 653-657, 1997.
[CrossRef]
[PubMed]
Shih SR, Li YS, Chiou CC, Suen PC, Lin TY, Chang LY, Huang YC, Tsao KC, Ning HC, Wu TZ, Chan EC. Expression of capsid protein VP1 for use as antigen
for the diagnosis of enterovirus 71 infection. J Med Virol. 61: 228-234, 2003.
[CrossRef]
Tian H, Yang QZ, Liang J, Dong SY, Liu ZJ, Wang LX. Clinical features and management outcomes of severe hand, foot, and mouth disease from an inland
Chinese community. Med Princ Pract. 21: 355-359, 2012.
[CrossRef]
[PubMed]
Uyen NQ, Hong HA, Cutting SM. Enhanced immunisation and expression strategies using bacterial spores as heat-stable vaccine delivery vehicles.
Vaccine. 25: 356-365, 2007.
[CrossRef]
[PubMed]
Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with
subunit VP1 vaccines and inactivated virus. Vaccine. 20: 895-904, 2001.
[CrossRef]
Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in
neonatal mice. J Biomed Sci. 7: 523-528, 2000.
[CrossRef]
[PubMed]
Yue YY, Li ZH, Li P, Song NN, Zhao YH, Meng H. Prokaryotic expression and initial identification of enterovirus 71 structural protein VP1. Shandong
Med J. 51: 22-24, 2011.
|
CITED
0
|
